

15 Edición

20  
21

**CELL** from the bench  
to the bedside  
and return

**THERAPY**

**SUMMER  
COURSE**

---

Directors:

Prof. José María Moraleda  
Prof. Salvador Martínez Pérez  
Prof. Damián García Olmos  
Prof. Robert Sackstein

**MURCIA - FROM 5-7 OF JULY- ONLINE**

More Information and Registration Form:  
[www.um.es/unimar](http://www.um.es/unimar) [www.campusmarenostrium.es](http://www.campusmarenostrium.es)

UNIVERSIDAD DE  
MURCIA



**TerCel** | isciii  
Red de Terapia Celular



Sociedad Española de  
Hematología y Hemoterapia



MINISTERIO  
DE CIENCIA  
E INNOVACION





**PLACE: VIRTUAL CLASSROOM  
UNIVERSIDAD DE MURCIA.**

Duration: 10 hours.

Max enrollment: 200 students.

Prize: 20 €.

## **DIRECTORS**

### **Prof. José María Moraleda Jiménez.**

Professor of Medicine. University of Murcia.  
Head Dpt. of Hematology and HSCT  
Program. Institute of Biomedical Research  
of Murcia - IMIB, Vigen de la Arrixaca  
University Hospital. Murcia, Spain.

### **Prof. Salvador Martínez Pérez.**

Director Institute of Neurosciences. UMH-  
CSIC. Professor of Human Anatomy and  
Embryology. University Miguel Hernández.  
Elche, Spain.

### **Prof. Damián García Olmo.**

Professor of Surgery. Chief of Department  
of Surgery. Fundación Jiménez Díaz  
University Hospital. Autonomous University  
of Madrid, Spain.

### **Prof. Robert Sackstein.**

Dean of the Herbert Wertheim College of  
Medicine and Senior VP for Health Affairs.  
Florida International University. Miami. FL,  
USA.

## **TARGET GROUP**

Collective of health professionals and  
students: haematologists and physicians of  
any other specialty interested in advanced  
therapies, as well as health professionals,  
researchers and university students of  
health and health-related degrees.

Other target groups are not professionals:  
groups involved who benefit from the  
information being shared in this course,  
such as patient associations, industry,  
companies, students, as well as other people  
and sectors of the population, with curiosity  
in the scientific field, who want obtain  
objective, critical and useful information to  
lay the foundations of appropriate  
knowledge.

## **AIMS**

The aim of this course is the diffusion of  
knowledge about Advanced cell therapies,  
including gene therapies, CAR cell  
immunotherapies, mesenchymal stromal  
cell-based therapies and new gene editing  
strategies and tools and their current  
applications.

Considering the impact on our society of the  
COVID-19 pandemic, we will also pay  
attention this year to some of the most  
important aspects of SARS-CoV-2 infection  
and its prevention and treatment.

The course is intended to provide a review  
of current clinical applications of advanced  
gene and cells therapies, a forum for  
scientific discussion with basic and clinical  
researchers that are experts in the field, and  
to present the achievements and challenges  
in this exciting and growing area of medical  
therapy. In addition, we will discuss some of  
the most important scientific issues  
concerning COVID-19 pandemic.

## **REGISTRATION RULES**

Please complete the Registration Form at  
the official website:

<https://www.um.es/unimar>

### **Payment Methods:**

Credit Card (Website).

Cash: only in person. Download the Payment  
form. Fill in the form and return it with your  
payment to Universidad Internacional del  
Mar. Banks: Sabadell, Bankia, Cajamar and  
Santander.

Once payment is made you will be enrolled  
in the course. Students must be enrolled and  
have a regular attendance to obtain the  
diploma or its equivalent.

## MESENCHYMAL STROMAL CELLS (MSC) GENE THERAPY: SCIENTIFIC BASIS FOR ITS THERAPEUTIC USE

### Session 1

#### Mesenchymal Stromal Cells and Therapy

##### 15:50-16:00 h. Opening Session

**16:00-16:15 h. MSC properties: the biological basis to become a cell medicine.**

**Prof. Agustín Zapata González.**

Professor of Cell Biology. Complutense University of Madrid. Spain.

**16:15-16:30 h. Production of cells and tissues in GMP facilities: a real challenge.**

**Prof. María Eugenia Fernández-Santos.**

Technical Director of the Cell Production Unit. Gregorio Marañón University Hospital. Research Institute Gregorio Marañón. Madrid, Spain.

**16:30-16:45 h. Microvesicles: the new therapeutic weapon from the MSC.**

**Prof. Fermín Sanchez-Guijo.**

Professor of Hematology. Hematology Department. University Hospital of Salamanca. University of Salamanca, Spain.

**16:45-17:00 h. Exofucosylation of Mesenchymal Stromal Cells stimulates their immunomodulatory properties.**

**Prof. David García Bernal.**

Cell Therapy Unit and HSCT Program. Institute of Biomedical Research – IMIB-Arrixaca, Virgen de la Arrixaca University Hospital. University of Murcia, Spain.

**17:00-17:20 h. MSC applications: Updated results**

**Prof. Damián García-Olmo.**

Professor of Surgery. Chief of Department of Surgery. Fundación Jiménez Díaz University Hospital. Autonomous University of Madrid, Spain.

**17:20-17:40 h. Questions´ time & Discussion.**

**Prof. Joan García López.**

Scientific Director. Banc de Sang i Teixits. Catalonia. Spain. Vice-president International Society for Cellular and GeneTherapy. Barcelona. Spain.

### Session 2

#### Gene Therapy and new gene editing tools

**17:40-18:00 h. Gene Therapy for Fanconi anemia.**

**Prof. Juan Bueren Roncero.**

Hematopoietic Innovative Therapies Division. CIEMAT. University of Madrid. Spain.

**18:00-18:20 h. Gene editing as tools for gene therapy.**

**Prof. Francisco Martin Molina.**

Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research (GENYO). Granada. Spain.

**18:20-18:40 h. Organoids design, 3-D bioprinting and cell mechanobiology: the future is here.**

**Prof. Nuria Monserrat Pulido.**

Principal investigator. Institute for Bioengineering of Catalonia (IBC). Barcelona. Spain

**18:40-19:00 h. Questions´ time & Discussion.**

**Prof. Salvador Martínez Pérez**

Professor of Neurosciences. Director Neurosciences Institute. Miguel Hernández University. Alicante. Spain.

## IMMUNE EFFECTOR CELL APPROACHES TO CURE DISEASES. THE CAR CELL INNOVATION

### Session 1

#### CAR-T cells

**16:00-16:15 h. Principles of immunotherapy. CAR-T cells.**

**Prof. Manel Juan Otero.**

Head Immunology Service, Hospital Clinic, Barcelona.  
Associate Professor, University of Barcelona, Spain.

**16:15-16:30 h. Present and future of CAR T- cells in the treatment of acute Lymphoblastic Leukemia.**

**Prof. Susana Rives Sola.**

Department of Hematology, Hospital Sant Joan de Deu, Barcelona, Spain.

**16:30-16:45 h. Present and future of CAR T- cells in the treatment of non-Hodgkin´s Lymphoma.**

**Prof. Pere Barba.**

Department of Hematology and Advanced Therapies, Vall d´Hebron Hospital, Barcelona, Spain.

**16:45-17:00h. Present and future of CAR T- cells in the treatment of Multiple Myeloma.**

**Prof Carlos Fernández de Larrea.**

Department of Hematology, Myeloma Unit, Hospital Clinic, Barcelona, Associate Professor, University of Barcelona, Spain

**17:00-17:15 h. Present and future of CAR T- cells in the treatment of Hodgkin´s disease.**

**Prof. Javier Briones Mejide.**

Director Clinical Hematology Unit, Hospital Santa Creu i Sant Pau, Associate Professor, Universidad Autonoma Barcelona, Spain.

**17:15-17:45 h. Questions´ time & Discussion.**

**Prof. Robert Sackstein.**

Dean of the Herbert Wertheim College of Medicine and Senior VP for Health Affairs, Florida International University, USA.

### Session 2

#### CAR-NK cells and new indications

**17:45-18:00 h. CAR-T cells against solid tumours.**

**Prof. Sonia Guedan Carrió.**

Hospital Clinic, Institut Jose Carreras, University of Barcelona, Spain.

**18:00-18:15 h. Improved CAR-T cells strategies to overcome tumor resistance.**

**Prof. Felipe Prosper Cardoso.**

Director of Cell Therapy Department, Co-director Hematology Department, University of Navarra, Spain.

**18:15-18:30 h. CAR-NK cells a new approach for hematologic malignancies.**

**Prof. Joaquín Martínez López.**

Professor of Hematology, Head Hematology Dpt, Hospital 12 de Octubre, Complutense University of Madrid, Spain.

**18:30-18:45 h. CAR-T cells in academic centres. The Spanish model.**

**Prof. Álvaro Urbano Ispizua.**

Hospital Clinic, Institut Josep Carreras, University of Barcelona, Spain.

**18:45-19:00 h. Questions´ time & Discussion.**

**Prof. Alejandro Madrigal.**

Director of the Anthony Nolan Trust, Chair of Hematology, London, UK.

## COVID-19 DISEASE.

## UP-TO-DATE SCIENTIFIC KNOWLEDGE

### Session 1

#### COVID-19 disease etiopathology

**16:00-16:20 h. SARS-CoV-2 Virological aspects including variants.**

**Francisco Diez Fuertes.**

National Center of Microbiology. Institute of Health Carlos III. Madrid. Spain.

**16:20-16:40 h. Covid Disease. Immunopathogenesis. The role of the immune system.**

**Prof. Alfredo Minguela.**

Professor of Medicine. Department of Immunology. Virgen de la Arrixaca University Hospital. Murcia, Spain.

**16:40-17:10 h. Covid Disease. Clinical Diagnosis and treatment. State of the art.**

**Prof. Santiago Moreno Guillen.**

Professor of Medicine. Head Infectious disease Dpt. Ramón y Cajal University Hospital Madrid. Spain.

**17:10-17:30 h. Covid Disease. Principles and practice of vaccination.**

**Prof. Luis Enjuanes**

Director Coronavirus group. National Center of Biotechnology. CNB-CSIC. Spain.

**17:30-17:40 h. Questions´ time & Discussion:**

**Prof. Elisa García Vázquez.**

Professor of Medicine. University of Murcia. IMIB-Arrixaca, Head Infectious disease Dpt. Virgen de la Arrixaca University Hospital. Murcia, Spain.

### Session 2

#### The critical role of the health care and research institutions against COVID-19

**17:40-18:00 h. Covid-19 National Epidemiologic study and its impact on public health. Up-to-date 2021.**

**Prof. Raquel Yotti Álvarez.**

Director. Institute of Health Carlos III. Ministry of Science and Innovation. Madrid. Spain.

**18:00-18:20 h. Covid-19 impact on the Spanish Transplant System. Up-to-date 2021.**

**Prof. Beatriz Domínguez-Gil.**

Director. National Transplant Organization (ONT). Madrid. Spain.

**18:20-18:40 h. Covid-19 research and treatments strategy. The AEMPS role.**

**Prof. María Jesús Lamas Diaz.**

Director of the Spanish Agency of Medicaments and Health Products. Madrid. Spain..

**18:40-19:00 h. Questions´ time & Discussion.**

**Prof. José María Moraleda Jiménez.**

Professor of Medicine. University of Murcia. Head, Hematology Dpt and HSCT Program. IMIB-Arrixaca, Virgen de la Arrixaca University Hospital. Murcia. Spain.

**19:00 h. Closing Ceremony**

# 05-06-07 / 07 / 2021 CELL THERAPY SUMMER COURSE



UNIVERSIDAD INTERNACIONAL DEL MAR  
Edificio Luis Vives, 3ª Planta  
30100 Campus de Espinardo, Murcia  
T. 868 88 8207 / 7262 / 3376 / 3360 / 3359  
unimar@um.es  
www.um.es/unimar  
VICERRECTORADO DE EMPLEO,  
EMPRENDIMIENTO Y SOCIEDAD

## Organiza

UNIVERSIDAD DE  
MURCIA



Sociedad Española de  
Hematología y Hemoterapia



TerCel | isciiii  
Red de Terapia Celular



## Colabora

